What factors influence motor complications in parkinson disease? A 10-year prospective study

Clinical Neuropharmacology

Volumn 35, Issue 1, 2012, Pages 1-5

  García Ruiz, Pedro J ^a   Del Val, Javier ^a   Fernández, Ignacio Mahillo ^a   Herranz, Antonio ^a  

^a Hospital UniversitarioFundación Jiménez Díaz   (Spain)

Author keywords

dyskinesias; gait freezing; motor complications; motor fluctuations; Parkinson disease; prospective study

Indexed keywords

ADULT; ARTICLE; DISEASE COURSE; DYSKINESIA; FEMALE; FOLLOW UP; GAIT DISORDER; GAIT FREEZING; HUMAN; MAJOR CLINICAL STUDY; MALE; MOTOR DYSFUNCTION; ONSET AGE; PARKINSON DISEASE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; SEX DIFFERENCE; UNIFIED PARKINSON DISEASE RATING SCALE;

ADULT; AGE FACTORS; AGE OF ONSET; AGED; ANTIPARKINSON AGENTS; DISABILITY EVALUATION; DISEASE PROGRESSION; DYSKINESIAS; FEMALE; GAIT DISORDERS, NEUROLOGIC; HUMANS; LOGISTIC MODELS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MOTOR ACTIVITY; MOTOR NEURON DISEASE; ODDS RATIO; PARKINSON DISEASE; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SEX FACTORS; STATISTICS, NONPARAMETRIC;

EID: 84855838907     PISSN: 03625664     EISSN: 1537162X     Source Type: Journal    
DOI: 10.1097/WNF.0b013e31823dec73     Document Type: Article

References (33)

1. Lees AJ, Hardy J, Revesz T. Parkinson's disease. Lancet 2009;373:2055-2066.
2. Ziemssen T, Reichmann H. Non-motor dysfunction in Parkinson's disease. Parkinsonism Rel Disord 2007;13:323-332. (Pubitemid 47212791)
3. Chaudhuri KR, Schapira AH. Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment. Lancet Neurol 2009;8:464-474.
4. Reardon K, Shiff M, Kempster PA. Evolution of motor fluctuations in Parkinson's disease: a longitudinal study over 6 years. Mov Disord 1999;14:605-611. (Pubitemid 30011453)
5. Fahn S. The spectrum of levodopa-induced dyskinesias. Ann Neurol 2000;47(suppl 1):2-11.
6. Schrag A, Ben-Shlomo Y, Quinn N. How common are complications of Parkinson's disease? J Neurol 2002;249:419-423. (Pubitemid 34304615)
7. Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from cumulative literature. Mov Disord 2001;16:448-458. (Pubitemid 36041148)
8. Kostic V, Przedborski S, Flaster E, et al. Early development of levodopa-induced dyskinesias and response fluctuations in young onset Parkinson's disease. Neurology 1991;41:202-205.
9. Sharma JC, Ross IN, Rascol O, et al. Relationship between weight, levodopa and dyskinesia: the significance of levodopa dose per kilogram body weight. Eur J Neurol 2008;15:493-496. (Pubitemid 351499195)
10. Poewe W, Mahlknecht P. The clinical progression of Parkinson's disease. Parkinsonism Relat Disord 2009;15S:28-32.
11. Selikhova M, Williams DR, Kempster PA, et al. A clinico-pathological study of subtypes in Parkinson's disease. Brain 2009;132: 2947-2957.
12. Paus S, Gadow F, Knapp M, et al. Motor complications in patients form the German Competence Network on Parkinson's disease and the DRD3 Ser9Gly polymorphism. Mov Disord 2009;24:1080-1084.
13. Sharma JC, Bachmann CG, Linazasoro G. Classifying risk factors for dyskinesia in Parkinson's disease. Parkinsonism Relat Disord 2010;16:490-497.
14. Parkinson Study Group. Impact of deprenyl and tocopherol treatment on Parkinson's disease in DATATOP patients requiring levodopa. Ann Neurol 1996;39:37-45.
15. Koller W, Hutton T, Tolosa E, et al. Immediate-release and controlled-release carbidopa/levodopa in PD. Neurology 1999;53:1012-1019.
16. Rascol O, Brooks D, Korczyn A, et al. A five years study of the incidence of dyskinesia in patients with early Parkinson's disease treated with ropinirole or levodopa. N Eng J Med 2000;342:1484-1491. (Pubitemid 30318272)
17. Parkinson Study Group. Pramipexole vs levodopa as initial treatment for Parkinson's disease. A randomized controlled trial. JAMA 2000;284:1931-1938.
18. Fahn S, Oakes D, Shoulson I, et al. Parkinson Study Group. Levodopa and the progression of Parkinson's disease. N Engl J Med 2004;351:2498-2508.
19. García Ruiz PJ, Meseguer E, del Val J, et al. Motor complications in Parkinson's disease: a prospective follow-up study. Clin Neuropharmacol 2004;27:49-52. (Pubitemid 38569174)
20. Katzenschlager R, Head J, Schrag A, et al. Parkinson's Disease Research Group of the United Kingdom. Fourteen-year final report of the randomized PDRG-UK trial comparing three initial treatments in PD. Neurology 2008;71:474-480.
21. Parkinson Study Group CALM Cohort Investigators. Long-term effect of initiating pramipexole vs levodopa in early Parkinson disease. Arch Neurol 2009;66:563-570.
22. Stocchi F, Rascol O, Kieburtz K, et al. Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Ann Neurol 2010;68:18-27.
23. Lang AE, Fahn S. Assessment of Parkinson's disease. In: Munsat TL, ed. Quantification of Neurological Deficit. Boston, MA: Butterworth-Heinemann; 1989:285-309.
24. Hughes A, Ben Shlomo Y, Daniel S, et al. What features improve the accuracy of clinical diagnosis in Parkinson's disease? Neurology 1992;42:1142-1146.
25. Koller W. How accurately can Parkinson's disease be diagnosed? Neurology 1992;42(suppl 1):6-16.
26. Lees AJ, Parkinson's Disease Research Group of the United Kingdom. Comparison of therapeutic effects and mortality data of levodopa and levodopa combined with selegiline in patients with early, mild Parkinson's disease. BMJ 1995;311:1602-1607. (Pubitemid 26002705)
27. Miyawaki E, Lyons K, Pahwa R, et al. Motor complications of chronic levodopa therapy in Parkinson's disease. Clin Neuropharmacol 1997;20:523-530. (Pubitemid 27512055)
28. Barbeau A. Six years of high level levodopa therapy in severely akinetic parkinsonian patients. Arch Neurol 1976;33: 333-338.
29. Shulman LM, Gruber-Baldini AL, Anderson KE, et al. The evolution of disability in Parkinson disease. Mov Disord 2008;23:790-796.
30. Van Gerpen JA, Kumar N, Bower JH, et al. Levodopa-associated dyskinesia risk among Parkinson disease patients in Olmsted County, Minnesota, 1976-1990. Arch Neurol 2006;63: 205-209. (Pubitemid 43261731)
31. Kumar N, Van Gerpen JA, Bower JH, et al. Levodopa-dyskinesia incidence by age of Parkinson's disease onset. Mov Disord 2005;20:342-344. (Pubitemid 40613295)
32. Ku S, Glass GA. Age of Parkinson's disease onset as a predictor for the development of dyskinesia? Mov Disord 2010;25:1177-1182.
33. Martinelli P, Contin M, Scagliones C, et al. Levodopa pharmacokinetics and dyskinesias: are there sex-related differences? Neurol Sci 2003;24:192-193. (Pubitemid 37304308)